Catalent Biologics recently commissioned two wrap-around labelling machines from Herma, for use in the production of biologics, including COVID-19 vaccines. The initiative involved delivering the machines in 10 weeks, making them validated and ready for production in another four weeks. Under normal circumstances, the company says, that process can take up to a year. Leadership of the project for the self-adhesive solutions firm was undertaken by its American subsidiary, Herma US, which worked closely on the order with representatives from the company’s headquarters in Filderstadt.
Catalent is a global player in the contract research, development and manufacturing of biologics and has production facilities in Europe and North America. The two machines acquired by the company are 132M HC wrap-around labellers, designed to meet the requirements of round pharmaceutical and healthcare products, including glass vials produced in high quantities. The modules offer optimisation-minded features such as rotary tables, digital position indicators and format sets that can be changed without tools for efficiency. Operation of the entire machine, including the camera and printer, can be controlled via an industrial panel PC.
“We appreciate the dedication and partnership HERMA’s team has shown us,” said Dominick Marino, VP of Global Procurement at Catalent. “These new labelling machines are vital to how quickly we can manufacture and package medicines for our customers and their patients.”
“Recognising the urgency in delivering labelling machinery during the pandemic, Herma decided to prebuild batches of the 132M at our factory in Germany,” said Peter Goff, CEO of Herma US. “A special project team was coordinated to expedite customer orders and fast track procurement of 3rd party items such as printers and vision systems. This has allowed delivery times to be dramatically reduced and allowed us to proudly assist with the worldwide drive to vaccinate the population as soon as possible.”
